NASDAQ$IART
Integra LifeSciences Holdings Corporation · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full-year ended December 31, 2020.
Integra LifeSciences reported Q4 2020 revenues of $388.6 million, a decrease of 1.6% compared to Q4 2019. GAAP earnings per diluted share were $1.09, compared to $0.18 in Q4 2019, and adjusted earnings per diluted share were $0.84, compared to $0.68 in Q4 2019.
- Reported revenues were $388.6 million, representing a decrease of 1.6% on a reported basis and a decrease of 1.5% on an organic basis compared to the fourth quarter 2019.
- Fourth quarter revenues increased 5.0% compared to the third quarter of 2020.
- GAAP earnings per diluted share were $1.09, compared to $0.18 in the fourth quarter 2019.
- Adjusted earnings per diluted share were $0.84, compared to $0.68 in the fourth quarter of 2019.
Headline financials
Revenue & EPS history
Integra LifeSciences · Revenue · Quarterly
$389M
Revenue by segment
Integra LifeSciences · $365M total across 4 segments · Q4 2020
- Neurosurgery$200M+9.4%54.9%
- Wound Reconstruction and Care$82.4M-1.2%22.6%
- Instruments$54M—14.8%
- Private Label$28.2M+2.0%7.7%
Forward guidance
For the first quarter 2021, the Company expects reported revenues in the range of $345 million to $355 million, representing reported growth of approximately (3.0%) to 0.0% and organic growth of approximately 0.0% to 3.0%. Adjusted earnings per diluted share are expected to be in a range of $0.54 to $0.58. For the full-year 2021, the Company expects revenues to be in a range of $1,520 million to $1,535 million, representing reported growth of 11% to 12% and organic growth of 12% to 13%. Adjusted earnings per diluted share are expected to be in a range of $2.86 to $2.93.
Tailwinds
- The Company expects reported revenues in the range of $345 million to $355 million for Q1 2021.
- The Company expects organic growth of approximately 0.0% to 3.0% for Q1 2021.
- Adjusted earnings per diluted share are expected to be in a range of $0.54 to $0.58 for Q1 2021.
- The Company expects revenues to be in a range of $1,520 million to $1,535 million for FY 2021.
- The Company expects organic growth of 12% to 13% for FY 2021.
Headwinds
- The Company is not providing a reconciliation to GAAP earnings per share.
- The financial impact and timing of divestitures, acquisitions, integrations, structural optimization and efforts to comply with the EU Medical Device Regulation are uncertain.
- These expense items could have a material impact on GAAP results.
- The Company will continue to monitor the ongoing uncertainty around the scope and duration of the pandemic and its impact on financial performance.
- The Company does not expect the ongoing impact of the pandemic to be uniform across all markets and product lines.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-0.2%
Avg return
Earnings day
-1.4%
Avg return
5 days after
-1.8%
Avg return
30 days after
51%
35 / 68 earnings
Positive
+29.2%
Q3 2024
Best reaction
-23.5%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +24.4% | +31.0% | +65.1% | |
| Q4 2025 | -2.1% | -8.9% | -20.6% | |
| Q3 2025 | -23.5% | -26.8% | -15.0% | |
| Q1 2025 | -20.9% | -27.3% | -22.3% | |
| Q4 2024 | +12.1% | +5.3% | -0.2% | |
| Q3 2024 | +29.2% | +28.5% | +25.1% | |
| Q2 2024 | -20.4% | -23.5% | -35.3% | |
| Q1 2024 | -13.2% | -10.0% | +9.9% | |
| Q4 2023 | -16.6% | -18.8% | -19.9% | |
| Q3 2023 | -4.5% | -5.8% | +6.3% | |
| Q2 2023 | -3.1% | -1.1% | -9.5% | |
| Q1 2023 | -6.2% | -5.5% | -34.7% | |
| Q4 2022 | +0.2% | +0.8% | -3.1% | |
| Q3 2022 | +11.1% | +12.7% | +21.1% | |
| Q2 2022 | -1.5% | -0.5% | -14.8% | |
| Q1 2022 | +2.9% | -0.2% | +2.5% | |
| Q4 2021 | +0.9% | +2.6% | -2.8% | |
| Q3 2021 | +7.1% | +7.5% | -5.3% | |
| Q2 2021 | -0.2% | -0.3% | +2.6% | |
| Q1 2021 | -2.0% | -3.4% | -9.9% | |
| Q4 2020 | -4.1% | -2.8% | -6.2% | |
| Q3 2020 | -7.0% | -4.5% | +19.5% | |
| Q2 2020 | +6.4% | +6.6% | -5.6% | |
| Q1 2020 | +1.5% | -2.8% | +7.9% | |
| Q4 2019 | +2.9% | -0.3% | -35.7% | |
| Q3 2019 | -7.7% | -5.1% | -2.0% | |
| Q2 2019 | +12.0% | +14.5% | +8.0% | |
| Q1 2019 | -3.1% | -2.3% | -7.7% | |
| Q4 2018 | +5.7% | +6.1% | +6.5% | |
| Q3 2018 | -12.6% | -13.5% | -13.9% | |
| Q2 2018 | -2.3% | -2.3% | -5.5% | |
| Q1 2018 | +9.8% | +12.7% | +16.7% | |
| Q4 2017 | -4.1% | -4.1% | +0.7% | |
| Q3 2017 | -9.1% | -8.2% | -4.9% | |
| Q2 2017 | -9.9% | -10.7% | -10.9% | |
| Q1 2017 | +4.6% | +5.1% | +12.1% | |
| Q4 2016 | -2.1% | -1.2% | -1.2% | |
| Q3 2016 | +1.6% | -3.4% | +3.8% | |
| Q2 2016 | +6.8% | +6.4% | +9.0% | |
| Q1 2016 | +6.7% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | +2.8% | — | — | |
| Q2 2015 | -0.1% | — | — | |
| Q1 2015 | +7.5% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -7.5% | — | — | |
| Q2 2014 | +1.0% | — | — | |
| Q1 2014 | -1.6% | — | — | |
| Q4 2013 | -3.9% | — | — | |
| Q3 2013 | +4.4% | — | — | |
| Q2 2013 | -2.2% | — | — | |
| Q1 2013 | +0.2% | — | — | |
| Q4 2012 | -4.8% | — | — | |
| Q3 2012 | -0.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2012 | +9.4% | — | — | |
| Q4 2011 | +1.2% | — | — | |
| Q3 2011 | -21.8% | — | — | |
| Q2 2011 | -5.3% | — | — | |
| Q1 2010 | +2.1% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | -0.7% | — | — | |
| Q4 2010 | -0.7% | — | — | |
| Q3 2010 | +2.2% | — | — | |
| Q3 2009 | +2.2% | — | — | |
| Q2 2009 | +6.2% | — | — | |
| Q2 2010 | +6.2% | — | — | |
| Q4 2009 | +6.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro